Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 13, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification of share transactions rather than a financial performance report.
Material Changes
The material change reported is a transfer of shares from the GlaxoSmithKline Employee Trust ("GSK Trust") to plan participants:
- Date of Transaction: January 12, 2006
- Transferring Entity: Abacus (GSK) Trustees Limited (Trustee of the GSK Trust)
- Recipient: Participants in the SmithKline Beecham Employee Share Option Plan 1991
- Volume: 12,547 Ordinary Shares
Management Commentary and Risks
The filing notes that the GSK Trust is a discretionary trust where all current and former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. Three directors—Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop—are noted as having an interest in the shares held in the GSK Trust in the same capacity as other employees. No specific risks, contingencies, or unusual items beyond this standard disclosure were detailed in the text.
Investor Verification Checklist
- Verify the total number of shares held by the GSK Trust prior to this transfer.
- Confirm the specific number of shares allocated to each participant in the SmithKline Beecham Employee Share Option Plan 1991.
- Review the full Disclosure Rule 3.1.4R(1)(b) requirements to ensure complete compliance regarding director interests.